Corcept Therapeutics (NASDAQ:CORT) Trading Up 7.9% – What’s Next?

Corcept Therapeutics Incorporated (NASDAQ:CORT) shares traded up 7.9% during mid-day trading on Friday . The company traded as high as $50.04 and last traded at $50.1850. 1,308,269 shares changed hands during trading, a decline of 31% from the average session volume of 1,893,790 shares. The stock had previously closed at $46.52.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Phase‑2 DAZALS data showed a large survival benefit in ALS (reported as an ~87% lower death risk), a potential material clinical and valuation catalyst if confirmed in later trials; this is the main near‑term driver of buying interest. Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk
• Positive Sentiment: Management raised its 2026 sales outlook, citing growth driven by Lifyorli and other commercial initiatives — a constructive sign that the company sees stronger revenue later in the year. CORT Q1 earnings match estimates, revenues miss, 2026 outlook raised
• Neutral Sentiment: Company reported Q1 revenue of $164.9M (up ~4.9% year‑over‑year) and provided a corporate update; revenue growth exists but is modest. Corcept Therapeutics Announces First-Quarter Financial Results and Provides Corporate Update
• Neutral Sentiment: Management commentary and the full earnings‑call transcript provide context on commercialization plans and the DAZALS program; investors will watch upcoming milestones and regulatory plans. Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 revenue missed Street expectations (consensus ~ $185.8M vs $164.9M reported), a shortfall that tempers the quarter’s headline and likely pressured some sellers. Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: GAAP EPS swung to a loss (-$0.30) versus $0.17 a year ago and missed some analyst models, highlighting near‑term profitability pressure despite longer‑term upside from clinical programs. Corcept: Q1 Earnings Snapshot

Analyst Ratings Changes

Several equities research analysts have issued reports on CORT shares. Canaccord Genuity Group boosted their price target on shares of Corcept Therapeutics from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Piper Sandler upped their target price on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday. Zacks Research cut shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Truist Financial upgraded Corcept Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, HC Wainwright cut their target price on Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Corcept Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $72.17.

Corcept Therapeutics Stock Up 10.3%

The company has a market cap of $5.51 billion, a P/E ratio of 62.96 and a beta of 0.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.92 and a quick ratio of 2.85. The business’s 50 day moving average price is $39.14 and its 200-day moving average price is $54.61.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.19). The business had revenue of $164.90 million during the quarter, compared to the consensus estimate of $185.83 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.17 EPS. On average, analysts anticipate that Corcept Therapeutics Incorporated will post 0.23 earnings per share for the current fiscal year.

Insider Activity at Corcept Therapeutics

In other news, Director G Leonard Baker, Jr. bought 100,000 shares of the stock in a transaction dated Tuesday, March 17th. The stock was bought at an average cost of $33.14 per share, with a total value of $3,314,000.00. Following the purchase, the director owned 1,146,631 shares of the company’s stock, valued at approximately $37,999,351.34. This represents a 9.55% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Joseph K. Belanoff sold 26,198 shares of the company’s stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the transaction, the chief executive officer owned 2,918,326 shares in the company, valued at approximately $146,120,582.82. The trade was a 0.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 86,198 shares of company stock valued at $3,668,569 over the last quarter. Corporate insiders own 20.80% of the company’s stock.

Institutional Trading of Corcept Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CORT. Hsbc Holdings PLC bought a new stake in Corcept Therapeutics in the first quarter valued at approximately $265,000. Whittier Trust Co. lifted its holdings in Corcept Therapeutics by 1,243.8% during the first quarter. Whittier Trust Co. now owns 5,402 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 5,000 shares in the last quarter. Simplify Asset Management Inc. acquired a new position in Corcept Therapeutics in the first quarter valued at about $1,522,000. Patten Group Inc. acquired a new stake in shares of Corcept Therapeutics during the first quarter worth about $519,000. Finally, Formidable Asset Management LLC lifted its holdings in shares of Corcept Therapeutics by 87.5% during the 1st quarter. Formidable Asset Management LLC now owns 11,681 shares of the biotechnology company’s stock valued at $471,000 after purchasing an additional 5,450 shares in the last quarter. 93.61% of the stock is owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.